Amedisys, Inc. (NASDAQ:AMED) Sees Large Decline in Short Interest

Amedisys, Inc. (NASDAQ:AMED - Get Free Report) saw a significant drop in short interest during the month of October. As of October 15th, there was short interest totalling 1,640,000 shares, a drop of 8.4% from the September 30th total of 1,790,000 shares. Currently, 5.1% of the shares of the company are sold short. Based on an average trading volume of 361,900 shares, the days-to-cover ratio is currently 4.5 days.

Institutional Trading of Amedisys

Large investors have recently bought and sold shares of the company. Innealta Capital LLC purchased a new position in shares of Amedisys in the second quarter valued at $64,000. Covestor Ltd grew its position in shares of Amedisys by 134.2% in the first quarter. Covestor Ltd now owns 780 shares of the health services provider's stock valued at $72,000 after purchasing an additional 447 shares in the last quarter. Signaturefd LLC grew its position in shares of Amedisys by 88.2% in the second quarter. Signaturefd LLC now owns 1,131 shares of the health services provider's stock valued at $104,000 after purchasing an additional 530 shares in the last quarter. CWM LLC grew its position in shares of Amedisys by 14.5% in the third quarter. CWM LLC now owns 2,190 shares of the health services provider's stock valued at $211,000 after purchasing an additional 277 shares in the last quarter. Finally, GAM Holding AG purchased a new position in shares of Amedisys in the second quarter valued at $275,000. 94.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on AMED shares. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $101.00 price target on shares of Amedisys in a research report on Thursday, July 25th. Deutsche Bank Aktiengesellschaft downgraded Amedisys from a "buy" rating to a "hold" rating and set a $101.00 price target for the company. in a research report on Monday, July 29th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Amedisys presently has a consensus rating of "Hold" and an average target price of $100.67.

Amedisys Stock Performance

NASDAQ:AMED traded down $0.08 during trading hours on Wednesday, reaching $95.25. The stock had a trading volume of 453,037 shares, compared to its average volume of 334,809. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.16 and a current ratio of 1.16. The stock has a 50 day simple moving average of $96.93 and a 200 day simple moving average of $95.60. Amedisys has a 12-month low of $89.55 and a 12-month high of $98.95. The stock has a market cap of $3.11 billion, a P/E ratio of -148.83, a price-to-earnings-growth ratio of 1.89 and a beta of 0.78.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.